Nov 20, 2026
FDA rejects Capricor's Duchenne muscular dystrophy cell therapy for second time
The FDA declined to approve Capricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy, citing significant issues with trial data reliability. This is the second rejection for the treatment, dealing a major blow to the company.
4 sources
00